Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Dec 13:8:F1000 Faculty Rev-2098.
doi: 10.12688/f1000research.20330.1. eCollection 2019.

Recent advances in understanding frontotemporal degeneration

Barbara Borroni  1 , Alberto Benussi  1
Affiliations
Review

Recent advances in understanding frontotemporal degeneration

Barbara Borroni et al. F1000Res. .

Abstract

Frontotemporal degeneration (FTD) is a heterogeneous spectrum of neurodegenerative disorders characterized by diverse clinical presentations, neuropathological characteristics, and underlying genetic causes. In the last few years, several advances in the knowledge of clinical and biological aspects have been accomplished and three major scenarios have emerged that will represent the core issues in the FTD scene over the next few years. Foremost, the development of cerebrospinal fluid and blood biomarkers as well as neuroimaging techniques will aid the pursuit of new diagnostic and prognostic markers able to identify the ongoing proteinopathy and predict disease progression, which is key in identifying and stratifying patients for enrolment in clinical trials as well as evaluating response to treatment. On the other hand, current research has focused on the first attempts to slow down or revert disease progression, with the identification of disease modulators associated with disease onset and the ongoing development of the first pharmacological treatments for both sporadic and genetic FTD. Future research will certainly improve our knowledge of FTD and possibly open up a new era of disease-modifying therapies for this still-orphan disorder.

Keywords: TDP43; Tau; biomarkers; diagnosis; frontotemporal dementia; treatment; trials.

PubMed Disclaimer

Conflict of interest statement

No competing interests were disclosed.No competing interests were disclosed.No competing interests were disclosed.

References

    1. Rademakers R, Neumann M, Mackenzie IR: Advances in understanding the molecular basis of frontotemporal dementia. Nat Rev Neurol. 2012;8(8): 423–34. 10.1038/nrneurol.2012.117 - DOI - PMC - PubMed
    1. Logroscino G, Piccininni M, Binetti G, et al. : Incidence of frontotemporal lobar degeneration in Italy: The Salento-Brescia Registry study. Neurology. 2019;92(10):e2355–e2363. 10.1212/WNL.0000000000007498 - DOI - PubMed
    1. Gorno-Tempini ML, Hillis AE, Weintraub S, et al. : Classification of primary progressive aphasia and its variants. Neurology. 2011;76(11):1006–14. 10.1212/WNL.0b013e31821103e6 - DOI - PMC - PubMed

    2. F1000 Recommendation

    1. Rascovsky K, Hodges JR, Knopman D, et al. : Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 2011;134(Pt 9):2456–77. 10.1093/brain/awr179 - DOI - PMC - PubMed
    1. Neary D, Snowden JS, Gustafson L, et al. : Frontotemporal lobar degeneration: A consensus on clinical diagnostic criteria. Neurology. 1998;51(6): 1546–54. 10.1212/wnl.51.6.1546 - DOI - PubMed